Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
- PMID: 33106326
- DOI: 10.1136/dtb.2020.000051
Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes
Abstract
Commentary on: Wiviott SD, Raz I, Bonaca MP, et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57. Commentary by: Dr Emma Magavern and Dr Teck Khong Clinical Pharmacology, St George's, University of London, UK Series Editor: Dr Teck Khong, DTB Associate Editor Clinical Pharmacology, St George's, University of London, UK.
Keywords: cardiovascular diseases; diabetes mellitus.
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared. Refer to the online supplementary files to view the ICMJE form(s).
Comment on
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical